Literature DB >> 18005732

CD8 T cell control of HSV reactivation from latency is abrogated by viral inhibition of MHC class I.

Mark T Orr1, Meredith A Mathis, Michael Lagunoff, Jilian A Sacks, Christopher B Wilson.   

Abstract

In humans, herpes simplex virus (HSV) establishes latency in sensory nerve ganglia from where it periodically reactivates, whereas in murine models, the virus efficiently establishes latency but rarely reactivates. HSV inhibits MHC class I antigen presentation to CD8 T cells efficiently in humans but poorly in mice, and whether this is a crucial determinant of HSV's ability to reactivate in humans remains uncertain. To test this, we generated a panel of recombinant HSVs that inhibit presentation by murine MHC class I mimicking the effect in humans. Antigen-specific CD8 T cells prevent the in vivo reactivation of wild-type HSV. Despite their presence in the ganglia of latently infected mice, CD8 T cells do not prevent the reactivation of recombinant HSVs that inhibit murine MHC class I in mice. These findings suggest that efficient inhibition of MHC class I by HSV is a key factor in its ability to reactivate in humans.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18005732      PMCID: PMC2034363          DOI: 10.1016/j.chom.2007.06.013

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  43 in total

1.  Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells.

Authors:  Lauren I Richie Ehrlich; Kouetsu Ogasawara; Jessica A Hamerman; Rayna Takaki; Alessandra Zingoni; James P Allison; Lewis L Lanier
Journal:  J Immunol       Date:  2005-02-15       Impact factor: 5.422

Review 2.  Herpes simplex virus infections.

Authors:  R J Whitley; B Roizman
Journal:  Lancet       Date:  2001-05-12       Impact factor: 79.321

3.  Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47.

Authors:  K Ahn; T H Meyer; S Uebel; P Sempé; H Djaballah; Y Yang; P A Peterson; K Früh; R Tampé
Journal:  EMBO J       Date:  1996-07-01       Impact factor: 11.598

4.  Correlation between herpes simplex virus type 1 rate of reactivation from latent infection and the number of infected neurons in trigeminal ganglia.

Authors:  J Maggioncalda; A Mehta; Y H Su; N W Fraser; T M Block
Journal:  Virology       Date:  1996-11-01       Impact factor: 3.616

5.  Longitudinal study of herpes simplex virus type 2 infection using viral dynamic modelling.

Authors:  Catherine M Crespi; William G Cumberland; Anna Wald; Lawrence Corey; Sally Blower
Journal:  Sex Transm Infect       Date:  2007-05-02       Impact factor: 3.519

Review 6.  Immune control of herpes simplex virus during latency.

Authors:  Kamal M Khanna; Andrew J Lepisto; Vilma Decman; Robert L Hendricks
Journal:  Curr Opin Immunol       Date:  2004-08       Impact factor: 7.486

Review 7.  Vaccines for herpes simplex virus infections.

Authors:  David M Koelle
Journal:  Curr Opin Investig Drugs       Date:  2006-02

8.  Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia.

Authors:  Kamal M Khanna; Robert H Bonneau; Paul R Kinchington; Robert L Hendricks
Journal:  Immunity       Date:  2003-05       Impact factor: 31.745

9.  Herpes simplex virus type 2 ICP47 inhibits human TAP but not mouse TAP.

Authors:  R Tomazin; N E van Schoot; K Goldsmith; P Jugovic; P Sempé; K Früh; D C Johnson
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

10.  Infected cell protein (ICP)47 enhances herpes simplex virus neurovirulence by blocking the CD8+ T cell response.

Authors:  K Goldsmith; W Chen; D C Johnson; R L Hendricks
Journal:  J Exp Med       Date:  1998-02-02       Impact factor: 14.307

View more
  17 in total

1.  Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease.

Authors:  Christopher S Morello; Michael S Levinson; Kimberly A Kraynyak; Deborah H Spector
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

2.  T cell response kinetics determines neuroinfection outcomes during murine HSV infection.

Authors:  Aisha G Lee; Jason M Scott; Maria Rita Fabbrizi; Xiaoping Jiang; Dorothy K Sojka; Mark J Miller; Megan T Baldridge; Wayne M Yokoyama; Haina Shin
Journal:  JCI Insight       Date:  2020-03-12

3.  Delaying the expression of herpes simplex virus type 1 glycoprotein B (gB) to a true late gene alters neurovirulence and inhibits the gB-CD8+ T-cell response in the trigeminal ganglion.

Authors:  Srividya Ramachandran; Katherine A Davoli; Michael B Yee; Robert L Hendricks; Paul R Kinchington
Journal:  J Virol       Date:  2010-06-23       Impact factor: 5.103

Review 4.  Control of HSV-1 latency in human trigeminal ganglia--current overview.

Authors:  Kathrin Held; Tobias Derfuss
Journal:  J Neurovirol       Date:  2011-12-03       Impact factor: 2.643

Review 5.  Illuminating viral infections in the nervous system.

Authors:  Dorian B McGavern; Silvia S Kang
Journal:  Nat Rev Immunol       Date:  2011-05       Impact factor: 53.106

6.  Persistent viral infection elevates central nervous system MHC class I through chronic production of interferons.

Authors:  Phi Truong; Sara Heydari; Lucile Garidou; Dorian B McGavern
Journal:  J Immunol       Date:  2009-08-28       Impact factor: 5.422

Review 7.  A cultured affair: HSV latency and reactivation in neurons.

Authors:  Angus C Wilson; Ian Mohr
Journal:  Trends Microbiol       Date:  2012-09-07       Impact factor: 17.079

8.  Development and pathogenic evaluation of recombinant herpes simplex virus type 1 expressing two fluorescent reporter genes from different lytic promoters.

Authors:  Srividya Ramachandran; Jared E Knickelbein; Christina Ferko; Robert L Hendricks; Paul R Kinchington
Journal:  Virology       Date:  2008-07-11       Impact factor: 3.616

Review 9.  The molecular basis of herpes simplex virus latency.

Authors:  Michael P Nicoll; João T Proença; Stacey Efstathiou
Journal:  FEMS Microbiol Rev       Date:  2012-01-10       Impact factor: 16.408

Review 10.  Immunological control of herpes simplex virus infections.

Authors:  Kevin P Egan; Sharon Wu; Brian Wigdahl; Stephen R Jennings
Journal:  J Neurovirol       Date:  2013-08-14       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.